Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: Effect of organic anions and cations by Olson, Stephen C. et al.
Journal of Pharmacokinetics and Biopharmaceutics, Vol. 24, No. 4, 1996 
Tubular Transport Mechanisms of Quinapril and 
Quinaprilat in the Isolated Perfused Rat Kidney: 
Effect of Organic Anions and Cations 
Alan R. Kugler, 1'2 Stephen C. Olson, 1 and David E. Smith 2'3 
Received August 11, 1995--Final Stepember 17, 1996 
The clearance mechanisms of quinapril and quinaprilat were probed using an isolated perfused rat 
kidney model. Sixty-four experiments were performed with drug in the absence and presence of 
classic inhibitors of the organic acid (i.e., probenecid and p-aminohippurate) and organic base 
(i.e., tetraethylammonium and quinine) transport systems of the proximal tubule, lnitial perfusate 
concentrations of quinapril and quinaprilat were approximately 2.36 ltM (or 1000 ng/ml ), and 
transport inhibitors were coperfused at 100-10,000 times the drugs" initial IzM concentrations. 
Quinapril and quinaprilat concentrations were determined in perfusate, urine, and perfusate 
ultrafiltrate using a reversed-phase HPLC procedure with radiochemical detection, coupled to 
liquid scintillation spectrometry. Perfusate protein binding was determined using an ultrafiltration 
method at 37~ Overall, the clearance ratios of quinapril (total renal clearance divided by 
fu- GFR) and quinaprilat (urinary clearance divided by fu. GFR) were significantly reduced, 
and in a dose-dependent manner, by the coperfusion of organic acids but not organic bases. The 
data demonstrate that the organic anionic secretory system is the primary mechanism by which 
quinapril and quinaprilat are transported into and across renal proximal cells. 
KEY WORDS: quinapril; quinaprilat; isolated perfused rat kidney; organic anions; organic 
cations; transport; metabolism. 
I N T R O D U C T I O N  
Angiotensin converting enzyme (ACE) inhibitors have become estab- 
lished therapy in two of the most common cardiac pathologies, namely, 
hypertension and congestive heart failure (1-4). ACE inhibitors may also 
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be useful in patients with diabetic nephropathy since they do not affect 
glucose or lipid metabolism while reducing renal vascular resistance and 
renal perfusion pressure (5). Although much is known about their mecha- 
nism of action and hemodynamic effects, much less is known about the renal 
disposition of ACE inhibitors. In particular, detailed aspects of their renal 
tubular transport mechanisms have yet to be fully elucidated. This may be 
important because cardiorenal homeostasis depends not only upon systemic 
effects on the renin-angiotensin-aldosterone (RAA) system but also upon 
local effects on the RAA system in kidney. Further, intrarenal metabolism 
of ACE inhibitor prodrugs to their pharmacologically active metabolites 
may contribute to their concentration-effect relationship. 
Previous studies in the isolated perfused rat kidney (rat IPK) have 
suggested that quinapril (Accupril | Parke-Davis) and quinaprilat are both 
actively transported by proximal tubular cells of the kidney (6). However, 
in the case of quinapril, the contribution of an active secretory process 
to its overall renal elimination was significantly complicated by intrarenal 
metabolism of drug to its de-esterified active form quinaprilat. Thus, of the 
total renal clearance for quinapril (i.e., excretory and metabolic), less than 
0.1% was cleared as unchanged drug and over 99% was cleared as intraren- 
ally formed quinaprilat. Notwithstanding this complication, the clearance 
ratio of quinapril was 41.0 (using the total renal clearance method; 
CLr[fU" GFR]), a value indicative of substantial net transport across the 
basolateral membrane of proximal tubular cells (6). Still, a precise mechanis- 
tic basis for quinapril and quinaprilat's renal tubular transport needs to be 
established. 
With this in mind, and given the fact that quinapril and quinaprilat are 
amphoteric compounds, the renal tubular handling of these drug species 
was further explored in the rat IPK using classic inhibitors of the organic 
acid and base transport systems of the proximal tubule. 
MATERIALS AND METHOD 
Animals 
Male Sprague-Dawley rats (body weight, 324-464 g) were used as kid- 
ney donors for the rat IPK preparations. All animals were allowed free 
access to food and water before experimentation. They were anesthetized 
with sodium pentobarbital (64.8/zg/g body weight, intraperitoneal) prior 
to surgery. 
Surgical Procedure 
The surgical approach adopted for the rat IPK system was based on 
the methods of Nishiitsutsuji-Uwo et al. (7) and Bowman (8) with minor 
modifications (6). 
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Perfusate Composition 
The kidney was perfused with a medium containing 6% bovine serum 
albumin, 0.1% glucose, and a mixture of 20 L-amino acids (9) in Krebs- 
Henseleit bicarbonate buffer (10). This perfusing medium was aerated with 
humidified O2:CO2 (95:5), and the pH was maintained throughout the 
experiment at 7.4. The perfusate volume was 100 ml. A detailed description 
of the perfusion apparatus has been reported previously (6). 
Chemicals 
3H-Quinapril and 3H-quinaprilat were obtained from Amergham 
Buchler GmbH & Co. KG, Braunschweig, Germany. Radiochemical purity 
of both compounds was determined to be >98% by HPLC. Specific activities 
were 20.1 and 22.2 mCi/mg for 3H-quinapril and 3H-quinaprilat, respec- 
tively. Unlabeled quinapril (hydrochloride) and quinaprilat (monohydrate) 
were obtained from Parke-Davis, Ann Arbor, MI. Purity of both compounds 
was determined to be >_99% by HPLC. 14C-Inulin (specific activity 2.5/zCi/ 
ms) was obtained from ICN Biochemicals Inc., Irvine, CA, and various 
transport inhibitors (probenecid, p-aminohippurate, tetraethylammonium, 
and quinine) were purchased from Sigma Chemical Co., St. Louis, MO. For 
the IPK studies, radiolabeled and unlabeled ACE inhibitors were combined 
for appropriate dilution, their solvents evaporated under a gentle stream of 
nitrogen, and reconstituted with a small volume of blank perfusate. Inulin 
was dissolved in distilled water (16.7/zCi/ml) and the transport inhibitors 
were dissoved in a small volume of blank perfusate. 
Experimental Protocol 
Once the kidney had been placed in the Plexiglas chamber, a 15-min 
equilibration period was allowed for stabilization of the preparation. 3H- 
Quinapril or 3H-quinaprilat (• and/or 14C-inulin (2.5/ICi) were 
introduced into the reservoir as bolus doses (considered time zero), and an 
additional 15 min were then allowed for drug disposition and hemodynamic 
stability to occur. The subsequent time (15-105 min) was divided into nine 
10-rain urine collection periods for the measurement of kidney function and 
urinary clearance parameters. The urine volume was measured, and its pH 
was determined immediately. Perfusate (1.5 ml) was sampled at the midpoint 
of each clearance interval. A 10-min perfusate sample was also collected 
during the 0-15 minute postbolus equilibration period. This additional 
sample was used for the calculation of drug disposition parameters only, in 
which 0-t or 0 - ~  time data were required (e.g., AUC). Losses in perfusate 
and urine because of sampling were minimized by isovolumetric replacement 
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with blank perfusate and buffer, respectively. All samples were frozen at 
< - 7 0 ~  until subsequent analysis. 
Sixty-four rat IPK experiments were performed with quinapril or quina- 
prilat in the absence and presence of inhibitors of the organic acid 
(i.e., probenecid and p-aminohippurate) and organic base (i.e., tetraethyl- 
ammonium and quinine) transport systems of the proximal tubule. Quinapril 
or quinaprilat was dosed at 200/.tCi (specific activity of 2.0 r after 
approximate 10 • dilution of the original material) so that initial perfusate 
concentrations approximated 2.36/2M (or 1000 ng/ml). Transport inhibi- 
tors were coperfused at 100-10,000 times the drugs' initial/2M concentra- 
tions. Inhibitor doses were first tested at the 1000 x/2M level; subsequent 
doses were determined according to the initial extent of inhibition or detri- 
mental effect on kidney function. 
Analytical 
3H-Quinapril and 3H-quinaprilat concentrations were determined in 
perfusate, urine, and perfusate ultrafiltrate using a reversed-phase HPLC 
procedure with radiochemical detection (11). ~4C-Inulin concentrations 
were determined by dual-label scintillation spectrometry, glucose by an 
enzymatic method, and sodium by flame photometry, as discussed previously 
(6). Additionally, for IPK studies in which quinaprilat was coperfused with 
p-aminohippurate (at 1000x and 10,000 x/IM), perfusate samples contain- 
ing p-aminohippurate were assayed using a reversed-phase HPLC procedure 
with UV detection (12). 
The protein binding of quinapril and quinaprilat was determined by 
ultrafiltration at 37~ The unbound fraction (fu) in perfusate samples, 
expressed as a percentage, was calculated as the perfusate ultra_filtrate drug 
concentration x 100 divided by the perfusate drug concentration. 
Data Analysis 
Functionality of the rat IPK was assessed primarily by measuring 
glomerular filtration rate (GFR), the fractional excretion of glucose 
(FEgl ..... ), and the fractional excretion of sodium (FEsodium). The renal 
clearance of inulin was taken to represent GFR. 
Given the significant metabolic component of quinapril elimination in 
the rat IPK (6), the drug's total renal clearance is represented by the sum 
of excretory and metabolic pathways (i.e., CLr = CLe+ C L m ) .  As such, the 
total renal clearance of quinapril was determined experimentally as 
CLr = Dose/A UCo- oo (1) 
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where A UCo-o~ is the area under the perfusate drug concentration-time 
curve from time zero to infinity. A U C o - ~  values were determined using the 
log-trapezoidal rule for experimental data and extrapolated to infinity using 
Cplast/2z, where 2z is the negative of the log-linear terminal slope of quinap- 
ril's perfusate concentration vs. time profile. The clearance ratio of quinapril 
(CR;  using the total renal clearance method) was then calculated as 
C R = C L r / ( f u  9 GFR) (2) 
The urinary clearance of quinapril was also calculated for each urinary 
collection period as 
CLe= U" m/Cprnid (3) 
where U is the concentration of quinapril in urine, Cpmid is its midpoint 
perfusate concentration, and V is the urinary flow rate. And finally, the 
metabolic clearance of quinapril was calculated as 
CLm = CLr - CLe (4) 
The urinary clearance of quinaprilat (after administration of quinapril 
or quinaprilat) was calculated for each urinary collection period as 
CL~ = U . g/Cpmid (5) 
where U is the concentration of quinaprilat in urine, Cpmid is its midpoint 
perfusate concentration, and V is the urinary flow rate. The clearance ratio 
of quinaprilat (CR; using the urinary clearance method) was then calculated 
as 
CR = CLe / ( fu"  GFR) (6) 
It should be appreciated that after quinaprilat dosing in rat IPK experiments, 
the urinary clearance and total renal clearance of quinaprilat are equivalent 
since the preformed metabolite is removed solely by renal excretion (i.e., 
Ctm--- 0) (6). 
Data are reported as the mean • SD, unless otherwise indicated. To test 
for statistically significant differences among treatments for a given param- 
eter, one-way analysis of variance (ANOVA) was performed. When the F 
ratio showed that there were significant differences among treatments, the 
Student-Newman-Keuls method of multiple comparisons was used to deter- 
mine which treatments differ. All statistical computations were performed 
using SAS 5.18 software (SAS Institute; Cary, NC) and a significance level 
of a = 0.05. 
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RESULTS 
Quinapril Administration 
Physiologic Function 
Perfusion pressure, perfusate flow rate, GFR, FE~j ...... FEsodium, urine 
flow rate, and urine pH were evaluated as indices of renal functionality in 
rat IPK experiments (Table I). Following quinapril administration, there 
were no significant differences in renal function for quinapril plus inhibitor 
treatments vs. quinapril alone, with the exception of FEsodium and urine flow 
rate in those experiments with p-aminohippurate. Although the reasons for 
these increased values is unclear, it is possible that p-aminohippurate may 
be acting as an osmotic diuretic, thereby promoting a greater output of 
sodium and urine. Overall, physiologic parameters were within the normal 
range of values for this technique (13-18), and were stable for the duration 
of each experiment. 
Disposition of Quinapril 
In the absence of transport inhibitors, quinapril is rapidly eliminated 
from the perfusate of IPK studies (6). However, when coperfused with 
organic acid inhibitors, the log-linear disappearance of quinapril from per- 
fusate was markedly reduced (Fig. 1). In fact, it appears that the elimination 
of quinapril was virtually shut down by probenecid at the 1,000 x/1M con- 
centration. These changes are due to a substantial and dose-dependent reduc- 
tion in the total renal clearance of quinapril in the presence of probenecid 
and p-aminohippurate (Table II) ; no change was observed in the total renal 
clearance of quinapril when coperfused with tetraethylammonium or quin- 
ine. Similar reductions were observed in the metabolic clearance of quinapril 
(~inhibitors) since the drug is almost completely metabolized. The urinary 
clearance of quinapril was negligible ( _<3.2% for all treatment groups) and 
due its substantial metabolism within the kidney, this parameter is a poor 
indicator of renal tubular transport mechanisms (6). As a result, clearance 
ratio (CR) of quinapril was determined using the total renal clearance 
method. In this form, calculation of CR is independent of the site of intra- 
renal metabolism and represents net transport across the basolateral mem- 
brane. As shown in Table II, the clearance ratio of quinapril was 
substantially reduced by probenecid and in a dose-dependent manner (24.7- 
fold at 1000 • A similar reduction in quinapril clearance ratio was 
observed with p-aminohippurate. Thus, perfusate concentrations of quinap- 
rilat were decreased since quinapril entry into proximal tubular cells was 
blocked along with its subsequent intrarenal metabolism (Fig. 2). In con- 
trast, tetraethylammonium and quinine caused an approximate 21-33% 
increase in the clearance ratio of quinapril. 
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Fig. 1. Perfusate concentration time curves for quinapril in the 
rat IPK after administration of quinapril (2.36/iM) alone (O, 
n=9), or when coperfused with probenecid at 100x#M 
(A, n=4), probenecid at 1000x/~M (A, n=4), p-aminohip- 
purate at 1000x/iM ([], n=4), p-aminohippurate at 
10,000 x r ( I ,  n=4), tetraethylammonium at 1000 x/IM 
(O, n=4), and quinine at 100xktM (0, n=4) . For the sake 
of clarity, only mean data are shown. 
Disposition of Quinaprilat 
A time-dependent change was observed in the clearance ratio of quin- 
aprilat (generated metabolite) after dosing quinapril alone and in the pres- 
ence of inhibitors (Fig. 3). This time dependence is predicted by Eq. (5), 
and reflects the fact that intrarenally formed quinaprilat either undergoes 
excretion or etttuxes back into the recirculating perfusate for subsequent 
reentry into the kidney, or both. As a result, quinaprilat excretion is domi- 
nated initially by quinapril to quinaprilat conversion and at later times 
by the urinary clearance of reabsorbed metabolite. The clearance ratio of 
preformed metabolite simply reflects its urinary clearance. Thus, the clear- 
ance ratios of intrarenally formed and preformed quinaprilat will ultimately 
be the same once quinapril has been effectively removed from the system 
(6). Interestingly, the clearance ratios of intrarenally formed quinaprilat 
were consistently lower in the p-aminohippurate as opposed to other treat- 
ment groups including probenecid (Fig. 3). 
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Fig, 2. Perfusate concentration-time curves for quinaprilat in 
the rat IPK after administration of quinapril (2.36/~M) alone 
(O, n =9), or when coperfused with probenecid at 100 x/~M 
(~x, n=4), probenecid at 1000 x pM (A, n=4), p-aminohip- 
purate at 1000x/~M (El, n=4), p-aminohippurate at 
10,000x/~M ( i ,  n=4), tetraethylammonium at 1000x,uM 
(0, n-4), and quinine at 100 x#M (&, n=4). For the sake 
of clarity, only mean data are shown. 
Quinaprilat Administration 
Physiologic Function 
Following quinaprilat administration, there were no significant 
differences in renal function for quinaprilat plus inhibitor treatments vs. 
quinaprilat alone, with one exception (Table III). FE~oa~m and urine flow 
rate were significantly greater when quinaprilat was coperfused with high 
dose p-aminohippurate (10 ,000•  This finding is similar to that 
described earlier for quinapril • p-aminohippurate and probably reflects an 
osmotic diuretic effect. Physiologic parameters were within the normal range 
of  values for this technique (13-18), and were stable for the duration of 
each experiment. 
Disposition of Quinaprilat 
Quinaprilat is slowly eliminated from the perfusate of IPK preparations 
(6) and, as a result, its renal clearance is more accurately determined as 
tirinary excretion rate divided by the corresponding midpoint perfusate 
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Fig. 3. Clearance ratio time curves for quinaprilat in the rat 
IPK after administration of quinapril (2.36/~M) alone (Q, 
n =9), or when coperfused with probenecid at 100 x ,uM ( ~, 
n = 41. probenecid at 1000 x #M (Ik, n = 4), p-aminohippurate 
at 1000 x ,u M ( [B, n = 4), p-aminohippurate at 10,1)00 x # M ( R, 
17 = 4). tetraethylammonium at 1000 x/~ M (~, n = 4), and quin- 
ine at 100 x ktM (0,  n=4). For the sake of clarity, only mean 
data are shown. 
concentrat ion.  A slow disappearance rate was also observed in these I P K  
studies (quinaprilat  4-inhibitors) fol lowing an initial distr ibution phase o f  
about  15 rain (Fig. 4). As shown in Table IV, the ur inary clearance o f  
preformed quinapri lat  was significantly reduced by organic acid but  no t  
organic base inhibitors. W h e n  differences in protein binding and  GFR were 
taken into account ,  the clearance ratio o f  preformed quinaprilat  was still 
reduced in a dose-dependent  manner  by probenecid  (5.7-fold at 1000 x # M )  
and by p-aminohippura te  (4.4-fold at 10,000 x p M ) ,  In  contrast ,  there was 
no difference in quinapri lat ' s  clearance ratio when coperfused with either 
t e t rae thy lammonium or quinine. 
Protein Binding 
On average, the fraction u n b o u n d  was 6.28-13.0% for quinapril  (after 
dosing quinapri l )  and 17.0-24.9% for  quinapri lat  (after dosing quinaprilat) .  
For  all I P K  studies, the protein binding o f  bo th  drug species was linear. 
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Fig. 4. Perfusate concentration-time curves for quinaprilat in 
the rat IPK after administration of quinaprilat (2.36/~M) alone 
( 0 ,  n=7) ,  or when coperfused with probenecid at 100 x lzM 
(S ,  n=4) ,  probenecid at 1000x/~M (A,  n~-4), p-aminohip- 
purate at 1000• (D, n=4) ,  p-aminoJaip!0urate at 
10,000x#M ( l l ,  n=4) ,  tetraethylammonjum a t  1000x/zM 
( ~ ,  n=4) ,  and quinine at 100• ( 0 ,  n=4) .  For the sake 
of clarity, only mean data are shown. 
Table IV. Disposition of Quinaprilat in the Isolated Perfused Rat Kidney AftEr Admin- 
istration of Quinaprilat ~ 
Treatment n fu (%) CLe (ml/min/g) CR b 
Qat alone 7 23.8 • 1.6a 2.18 • 0.54, 3.85 + 0.73~ 
Qat+  100 x PRO 4 24.94-2.5a 0.903 • 0 .170~ 1.13• 
Qat+ 1000 x PRO 4 22.64- 1.3a 0,516 • 0.059~ 0.681 • 0.055c 
Qat+ 1000 x PAH 4 19.54-3.6b 1.10 +0.33b,o 2.21 • 
Qat + 10,000 x PAH 4 22.7• 0.581 4-0.134~ 0.875 • 
Qat + 1000 x TEA 4 17.1 • 1.64 • 0.35a,u 3.04• 
Qat + 100 x QUI 4 17.0 • 0.2b 1.67 • 0.19a,b 3.47 • 0.40a 
aSame as footnote a, Table III. CL~ has been normalized by kidney dry weight (g). 
bClearance ratio (CR) was calculated for quinaprilat using the urinary clearance method 
[Eq. (6)1. 
Although statistical differences were evident among some of the treatment 
groups (Tables II and IV), protein binding alterations were probably due 
to the inherent variability in experimental conditions (e.g., perfusate compo- 
sition, assay). A competitive displacement of quinapril or quinaprilat by the 
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inhibitors is unlikely since, in most cases, the fraction unbound is unchanged 
or reduced. Regardless, the clearance ratio calculations correct for any 
differences that may be present during the study conditions. 
Metabolic Disposition 
In all rat IPK experiments (~=inhibitors), quinapril was not metabolized 
to any other drug species besides quinaprilat. In addition, no further metabo- 
lites of either generated or preformed quinaprilat were found. Thus, these 
whole organ studies were consistent with the metabolic profile observed from 
in vitro (19) and in vivo (20) experiments in rats. 
DISCUSSION 
Few studies have directly addressed the mechanisms of renal tubular 
transport for the ACE inhibitors. In an in vivo rat study, Lin et al. (21) 
demonstrated that probenecid, p-aminohippurate, and quinine had no effect 
on the renal clearance of lisinopril. Based on this finding and the fact that 
the drug's clearance ratio was 1.01 (using the urinary clearance method; 
CLe / [ fu .  GFR]), the authors concluded that lisinopril was eliminated in 
the kidney by glomerular filtration alone. In contrast, the concomitant 
administration of probenecid and p-aminohippurate caused a profound 
decrease in the clearance ratio of enalaprilat (2.72 alone vs. 1.10 in the 
presence of probenecid vs. 1.24 in the presence of p-aminohippurate; urinary 
clearance method). These results and the lack of effect by quinine indicated 
that, unlike lisinopril, enalaprilat was secreted by the organic anion transport 
system. In a study using isolated red blood cell-perfused rat kidneys, de 
Lannoy et al. (22) observed that the clearance ratios of enalapril and enalap- 
rilat were approximately 0.5 and unity, respectively (using the urinary clear- 
ance method), in the recirculating constant-pressure model. Based on these 
observations, the authors concluded that while enalapril was renally cleared 
by a net reabsorption process, enalaprilat was cleared by net filtration. How- 
ever, the former conclusion is tenuous since this method of analysis did not 
account for enalapril's significant extent of metabolism within the kidney. 
In fact, in the presence of intrarenal metabolism it may be inappropriate to 
designate the "net renal transport process" of a drug (23). Thus, as an 
alternative method of data analysis, we estimated the clearance ratio of 
enalapril at 7 to 8 (using the total renal clearance method), a result indicative 
of extensive net transport across the basolateral membrane of proximal 
tubular cells. Although clarification of enalapril's renal tubular transport 
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could be obtained with the use of known competitive inhibitors of secretory 
transport, this option was not pursued (22). 
Human studies have suggested that many ACE inhibitors, including 
captopril, enalapril and enalaprilat, and quinapril and quinaprilat, are 
renally cleared by glomerular filtration and tubular secretion (1,24,25). 
Further, it appears that these ACE inhibitors are transported via the non- 
specific organic acid secretory pathway. As a result, probenecid pretreatment 
has been shown to significantly reduce the renal clearance of captopril (26) 
and enalapril and enalaprilat (27), whereas hydrochlorothiazide coadminis- 
tration resulted in a decrease in the renal clearance of enalaprilat but not 
enalapril (28). Drug interaction studies with organic cations suggest that 
these ACE inhibitors do not utilize the nonspecific organic base secretory 
pathway (3,4,29,30). However, in general, many of the drug interactions 
reported in humans are difficult to interpret given the lack of renal clearance 
measurements, the limited number of dose combinations studied for ACE 
inhibitor • transport inhibitor, and the potential effect of urine flow altera- 
tions on the renal clearance of ACE inhibitor 4-diuretic. Further, intrarenal 
metabolism may complicate the interpretation of renal excretion data in 
humans, as was demonstrated in rat IPK experiments (6,22). 
In the present rat IPK studies, it was observed that the clearance ratio 
of quinapril was substantially reduced in a dose-dependent manner by both 
probenecid and p-aminohippurate (Table II). As a consequence of this 
apparent competitive inhibition, perfusate concentrations of quinaprilat 
were decreased since quinapril's entry into the renal proximal cell was 
blocked along with its subsequent intrarenal metabolism (Fig. 2). In con- 
trast, tetraethylammonium and quinine did not attenuate the clearance ratio 
of quinapril. In fact, the quinapril clearance ratio was significantly increased 
by these substrates, and may reflect an effect on quinapril reabsorption. 
Although the mechanism by which this effect occurs is unclear at present, 
it was not due to a urine flow- or pH-dependent reduction in passive reab- 
sorption since these physiological parameters were unchanged in the quinap- 
ril• quinine treatments (Table II). An alternate 
hypothesis is that quinapril may be undergoing reabsorption by a carrier- 
mediated system (e.g., proton/peptide cotransporter). If so, then the renal 
cell-to-lumen transport of organic cations across the brush border membrane 
(via cation/proton exchanger) may have resulted in a less favorable micro- 
climate pH such that quinapril reabsorption was reduced and its clearance 
ratio increased. This observation is supported by the fact that quinapril is 
a tripeptide analog and that other ACE inhibitors have been shown to utilize 
the peptide transporter in intestine (31,32). 
After quinaprilat administration (Table IV), the clearance ratio of 
quinaprilat was reduced in a dose-dependent manner by both organic acid 
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transport inhibitors. Although there was a trend for quinaprilat clearance 
ratio to decrease when coperfused with tetraethylammonium or quinine, this 
difference was not statistically significant. It was also found that only p- 
aminohippurate caused a substantial and consistent decrease in the clearance 
ratio of generated metabolite (Fig. 3). The apparent inability of probenecid 
(but not p-aminohippurate) to inhibit quinaprilat transport at the brush 
border membrane cannot be explained by differences in the perfusate concen- 
trations of accumulating metabolite. As shown in Fig. 2, quinaprilat perfus- 
ate levels were virtually identical after quinapril plus 100 x ktM probenecid 
vs. quinapril plus 10,000x/.tM p-aminohippurate treatments, but their 
effects differed markedly. An effect of inhibitors on cellular uptake from 
tubular fluid is also unlikely since in vivo micropuncture studies have demon- 
strated that quinaprilat reabsorption is minimal (<10%) (33). Thus, the 
data suggest a selective inhibition by probenecid at the basolateral 
membrane, whereas p-aminohippurate may inhibit at the basolateral and 
brush border membranes. 
In analyzing the temporal aspects of quinaprilat clearance ratio (after 
dosing quinaprilat), this parameter was observed to be relatively constant 
for all treatments except that of low dose p-aminohippurate (Fig. 5). To 
further investigate this phenomenon, the clearance ratio of quinaprilat was 
evaluated with respect to p-aminohippurate perfusate concentrations. As 
shown in Fig. 6, perfusate concentrations of p-aminohippurate were 
sufficiently high during the 10,000 x/ IM treatment (>5000 ~M) such that 
the quinaprilat clearance ratio was diminished but constant over time. In 
contrast, p-aminohippurate perfusate concentrations fell rapidly during the 
1000 x/~M treatment (<5000 pM) and, as a result, the efficiency of inhibi- 
tion decreased while the quinaprilat clearance ratio increased with time (i.e., 
with reduced levels of inhibitor). 
Although not specifically addressed, it is possible that quinapril and 
quinaprilat may interfere with each other at the level of transport. However, 
this omission does not detract from our conclusion that quinapril and quina- 
prilat are both transported into and across renal proximal cells by the organic 
acid secretory pathway. This is so because after dosing quinapril, significant 
reductions in the clearance ratio of quinapril were observed in the presence 
of anionic inhibitors (Table II) even though less quinaprilat was being 
formed (Fig. 2). And after dosing quinaprilat, there is no quinapril present 
to have an effect. 
Quinapril (possessing an amino group, pKa 5.4 and a carboxyl group, 
pKa 2.8) and quinaprilat (possessing an amino group, pKa=8.3 and two 
carboxyl groups, pKas 2.7, 4.5) are both amphoteric compounds. At physio- 
logical pH, quinapril is completely ionized at its carboxyl group and com- 
pletely unionized at its amino group; quinaprilat is completely ionized at 
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Fig. 5. Clearance ratio-time curves for quinaprilat in the rat 
IPK after administration of quinaprilat (2.36/~M) alone (Q, 
n = 7), or when coperfused with probenecid at 100 x #M (k~, 
n = 4), probenecid at 1000 x pM ( Jr, n = 4), p-aminohippurate 
at 100~3 x btM ([~, n = 4), p-aminohippurate at 10,000 x/~ M (11, 
n= 4), tetraethylammonium at 1000 x/~M (<3, n =4), and quin- 
ine at 100 x/~M (0, n =4). For the sake of clarity, only mean 
data are shown. 
both carboxyl groups and about  90% ionized at its amino group. Since both 
quinapril and quinaprilat are anionic in nature, they would be expected to 
utilize the organic acid transport  system of the proximal tubule. This expecta- 
tion was confirmed experimentally with the use of  potent competitive inhibi- 
tors of  the renal anionic t ransport  system but  not  by inhibitors of the renal 
cationic transport  system. Mechanistically, it is clear that for organic acid 
secretion, the active step in transport  occurs at the basolateral surface, that  
negligible transport  occurs paracellularly, and that facilitated diffusion is 
likely at the luminal surface (34). Thus, the anionic inhibitors (probenecid, 
p-aminohippurate)  may block transport  o f  quinapril and quinaprilat into 
the cell at the basolateral membrane  (i.e., active step) and /o r  t ransport  into 
the tubular fluid at the brush border  membrane  (i.e., facilitated step). The 
likelihood of  a specific effect o f  inhibitors on esterase activity seems remote, 
and we are unaware of  such an occurrence. 
Quinapril and quinaprilat were coperfused with high inhibitor concen- 
trations in order to probe their renal tubular t ransport  mechanisms. Plasma 
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Fig. 6. Relationship between quinaprilat clearance ratio and 
perfusate concentration of p-aminohippurate in the rat IPK 
when quinaprilat (2.36/JM) was coperfused with p-aminohip- 
purate at 1000 x/iM (D, n=4) and 10,000x/iM (11, n=4). 
Data are displayed as mean 4-SEM. 
concentrations of probenecid are observed at 700/.tM which is about 300 
times greater than the initial perfusate concentration of ACE inhibitor. Thus, 
drug is being coperfused with probenecid (100-1000 x/JM) at clinically 
relevant concentrations. Plasma concentrations of p-aminohippurate (PAH) 
are observed at 3090/~M which is about 1300 times greater than the initial 
perfusate concentration of ACE inhibitor. Thus, drug is being coperfused 
with PAH (1000 x/~M) at clinically relevant concentrations. PAH, at the 
higher dose level (10,000 x/JM) was necessary because of its rapid elimina- 
tion from the perfusate with time, thus, effecting its ability to inhibit quinap- 
rilat in a consistent manner (see Figs. 5 and 6). 
Overall, the inhibition data support our initial studies with quinapril 
and quinaprilat alone in the rat IPK (6). In this regard, quinapril and quinap- 
rilat are actively secreted by the kidney. Further, quinapril is extensively 
metabolized by the kidney to quinaprilat, a process coupled to its net tubular 
transport across the basolateral membrane of proximal tubular cells. Finally, 
the results demonstrate that the organic anionic secretory system is the 
primary mechanism by which quinapril and quinaprilat are transported into 
and  across renal proximal cells. 
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